Nitrosation-dependent caveolin 1 phosphorylation, ubiquitination, and degradation and its association with idiopathic pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 4, 2013, Pages 816-830

  Bakhshi, Farnaz R ^a   Mao, Mao ^a   Shajahan, Ayesha N ^a   Piegeler, Tobias ^a   Chen, Zhenlong ^a   Chernaya, Olga ^a   Sharma, Tiffany ^a   Elliott, W Mark ^b   Szulcek, Robert ^c   Bogaard, Harm Jan ^c   Comhair, Suzy ^d   Erzurum, Serpil ^d   Van Nieuw Amerongen, Geerten P ^a,c   Bonini, Marcelo G ^a   Minshall, Richard D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Endothelial dysfunction; Endothelial nitric oxide synthase (eNOS); Oxidative stress; Pulmonary arterial hypertension (PAH); Src

Indexed keywords

EID: 84907858757     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674753     Document Type: Article

References (65)

1. Maniatis N, Chernaya O, Shinin V, Minshall R. Caveolins and lung function. Adv Exp Med Biol 2012;729:157-179.
2. Stan R-V. Structure and function of endothelial caveolae. Microsc Res Tech 2002;57:350-364.
3. Minshall RD, Sessa WC, Stan RV, Anderson RGW, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003;285:L1179-L1183.
4. Stan RV. Structure of caveolae. Biochim Biophys Acta 2005; 1746:334-348.
5. Rothberg KG, Heuser JE, Donzell WC, Ying Y-S, Glenney JR, Anderson RGW. Caveolin, a protein component of caveolae membrane coats. Cell 1992;68:673-682.
6. Schlegel A, Volonté D, Engelman JA, et al. Crowded little caves: structure and function of caveolae. Cell Sig 1998;10: 457-463.
7. Kronstein R, Seebach J, Großklaus S, et al. Caveolin-1 opens endothelial cell junctions by targeting catenins. Cardiovasc Res 2012;93:130-140.
8. Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Caveolae and caveolin in transmembrane signaling: implications for human disease. Cardiovasc Res 2006;70:42-49.
9. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995;92:1381-1385.
10. Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Medi 2004;37:1010-1017.
11. Xu W, Kaneko FT, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004;18: 1746-1748.
12. Mathew R. Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011;2011:573432.
13. Achcar ROD, Demura Y, Rai PR, et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
14. Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012;5:336-343.
15. Place AT, Chen Z, Bakhshi FR, Liu G, O’Bryan JP, Minshall RD. Cooperative role of caveolin-1 and C-terminal Src kinase binding protein in C-terminal Src kinase-mediated negative regulation of c-Src. Mol Pharmacol 2011;80:665-672.
16. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, Sessa WC. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA 2005;102:761-766.
17. Chen Z, Bakhshi FR, Shajahan AN, et al. Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Mol Biol Cell 2012;23:1388-1398.
18. Mao M, Sudhahar V, Ansenberger-Fricano K, et al. Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway. Free Radic Biol Med 2012;52:427-435.
19. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005;97:95-98.
20. Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769.
21. Konduri GG, Bakhutashvili I, Eis A, Pritchard K. Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 2007;292:H1812-H1820.
22. Oishi PE, Wiseman DA, Sharma S, et al. Progressive dysfunction of nitric oxide synthase in a lamb model of chronically increased pulmonary blood flow: a role for oxidative stress. Am J Physiol Lung Cell Mol Physiol 2008;295:L756-L766.
23. Lee H, Woodman SE, Engelman JA, et al. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). J Biol Chem 2001;276:35150-35158.
24. Sverdlov M, Shinin V, Place AT, Castellon M, Minshall RD. Filamin A regulates caveolae internalization and trafficking in endothelial cells. Mol Biol Cell 2009;20:4531-4540.
25. Comhair SAA, Xu W, Mavrakis L, Aldred MA, Asosingh K, Erzurum SC. Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol 2012;46:723-730.
26. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE 2001;2001: pl1.
27. Kinter M, Sherman NE. Protein sequencing and identification using tandem mass spectrometry. Hoboken, NJ: Wiley, 2000.
28. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev 2007;15:143-149.
29. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004;110:1499-1506.
30. Masri FA, Xu W, Comhair SAA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L548-L554.
31. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007;75:247-260.
32. Barsacchi R, Perrotta C, Bulotta S, Moncada S, Borgese N, Clementi E. Activation of endothelial nitric-oxide synthase by tumor necrosis factor-α: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3′ kinase, and Akt. Mol Pharmacol 2003;63: 886-895.
33. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-475.
34. Fernandez I, Ying Y, Albanesi J, Anderson RGW. Mechanism of caveolin filament assembly. Proc Natl Acad Sci USA 2002;99:11193-11198.
35. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L1-L8.
36. Cruz JA, Bauer EM, Rodriguez AI, et al. Chronic hypoxia induces right heart failure in caveolin-1−/− mice. Am J Physiol Heart Circ Physiol 2012;302:H2518-H2527.
37. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:897-908.
38. Rougier J-S, Gavillet B, Abriel H. Proteasome inhibitor (MG132) rescues Nav1.5 protein content and the cardiac sodium current in dystrophin-deficient mdx5cv mice. Front Physiol 2013;4:51.
39. Glenney JR, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 1992; 89:10517-10521.
40. Tiruppathi C, Naqvi T, Wu Y, Vogel SM, Minshall RD, Malik AB. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA 2004;101:7699-7704.
41. Ghitescu L, Fixman A, Simionescu M, Simionescu N. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: receptormediated transcytosis. J Cell Biol 1986;102:1304-1311.
42. Minshall RD, Tiruppathi C, Vogel SM, et al. Endothelial cell-surface gp60 activates vesicle formation and trafficking via Gi-coupled Src kinase signaling pathway. J Cell Biol 2000; 150:1057-1070.
43. Schubert W, Frank PG, Razani B, Park DS, Chow C-W, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001;276:48619-48622.
44. Bendayan M, Rasio EA. Transport of insulin and albumin by the microvascular endothelium of the rete mirabile. J Cell Sci 1996;109:1857-1864.
45. Vasile E, Simionescu M, Simionescu N. Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J Cell Biol 1983;96:1677-1689.
46. Hu G, Place AT, Minshall RD. Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem Biol Interact 2008;171:177-189.
47. Schnitzer JE, Liu J, Oh P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J Biol Chem 1995;270:14399-14404.
48. Schnitzer JE, Oh P, Jacobson BS, Dvorak AM. Caveolae from luminal plasmalemma of rat lung endothelium:microdomains enriched in caveolin, Ca2+-ATPase, and inositol trisphosphate receptor. Proc Natl Acad Sci USA 1995;92:1759-1763.
49. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/ STAT signalling proteins in plasmalemmal caveolae. Biochem J 2000;351:257-264.
50. Garcıá-Cardeña G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA 1996;93:6448-6453.
51. Lisanti MP, Scherer PE, Vidugiriene J, et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 1994;126:111-126.
52. Liu J, Oh P, Horner T, Rogers RA, Schnitzer JE. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 1997;272:7211-7222.
53. Annabi B, Lachambre M, Bousquet-Gagnon N, Pagé M, Gingras D, Béliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001;353:547-553.
54. Chun M, Liyanage UK, Lisanti MP, Lodish HF. Signal transduction of a G protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Natl Acad Sci USA 1994;91:11728-11732.
55. Oh P, Schnitzer JE. Segregation of heterotrimeric G proteins in cell surface microdomains: Gq binds caveolin to concentrate in caveolae, whereas Gi and Gs target lipid rafts by default. Mol Biol Cell 2001;12:685-698.
56. Stenmark KR, Meyrick B, Galiè N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
57. Fijalkowska I, Xu W, Comhair SAA, et al. Hypoxia inducible-factor 1α regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Path 2010; 176:1130-1138.
58. Mercier I, Jasmin J-F, Pavlides S, et al. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest 2009;89:614-623.
59. Hill MM, Bastiani M, Luetterforst R, et al. PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell 2008;132:113-124.
60. Liu L, Brown D, McKee M, et al. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab 2008;8:310-317.
61. Parkar NS, Akpa BS, Nitsche LC, et al. Vesicle formation and endocytosis: function, machinery, mechanisms, and modeling. Antioxid Redox Signal 2009;11:1301-1312.
62. Bernatchez P, Sharma A, Bauer PM, Marin E, Sessa WC. A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice. J Clin Invest 2011;121:3747-3755.
63. Kirchner P, Bug M, Meyer H. Ubiquitination of the Nterminal region of caveolin-1 regulates endosomal sorting by the VCP/p97 AAA-ATPase. J Biol Chem 2013;288:7363-7372.
64. Hayer A, Stoeber M, Ritz D, Engel S, Meyer HH, Helenius A. Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol 2010; 191:615-629.
65. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001;276:38121-38138.